JP7794757B2 - 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ - Google Patents

血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ

Info

Publication number
JP7794757B2
JP7794757B2 JP2022561400A JP2022561400A JP7794757B2 JP 7794757 B2 JP7794757 B2 JP 7794757B2 JP 2022561400 A JP2022561400 A JP 2022561400A JP 2022561400 A JP2022561400 A JP 2022561400A JP 7794757 B2 JP7794757 B2 JP 7794757B2
Authority
JP
Japan
Prior art keywords
ofatumumab
pharmaceutical composition
treatment
cell
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022561400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521754A (ja
JP2023521754A5 (https=
Inventor
ピンギリ，ラトネーカー
メルシュヘムケ，マルティン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2023521754A publication Critical patent/JP2023521754A/ja
Publication of JP2023521754A5 publication Critical patent/JP2023521754A5/ja
Priority to JP2025151221A priority Critical patent/JP2026009900A/ja
Application granted granted Critical
Publication of JP7794757B2 publication Critical patent/JP7794757B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022561400A 2020-04-09 2021-04-09 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ Active JP7794757B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025151221A JP2026009900A (ja) 2020-04-09 2025-09-11 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20169007.0 2020-04-09
EP20169007 2020-04-09
EP20176057 2020-05-22
EP20176057.6 2020-05-22
US202063076628P 2020-09-10 2020-09-10
US63/076,628 2020-09-10
US202163166054P 2021-03-25 2021-03-25
US63/166,054 2021-03-25
PCT/EP2021/059285 WO2021204994A1 (en) 2020-04-09 2021-04-09 Ofatumumab for treating ms while maintaining serum igg

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025151221A Division JP2026009900A (ja) 2020-04-09 2025-09-11 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ

Publications (3)

Publication Number Publication Date
JP2023521754A JP2023521754A (ja) 2023-05-25
JP2023521754A5 JP2023521754A5 (https=) 2024-04-19
JP7794757B2 true JP7794757B2 (ja) 2026-01-06

Family

ID=75362645

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022561400A Active JP7794757B2 (ja) 2020-04-09 2021-04-09 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ
JP2025151221A Pending JP2026009900A (ja) 2020-04-09 2025-09-11 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025151221A Pending JP2026009900A (ja) 2020-04-09 2025-09-11 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ

Country Status (12)

Country Link
US (1) US20230151106A1 (https=)
EP (3) EP4707302A2 (https=)
JP (2) JP7794757B2 (https=)
KR (1) KR20220166827A (https=)
CN (1) CN115427068A (https=)
AU (1) AU2021253674A1 (https=)
BR (1) BR112022019038A2 (https=)
CA (1) CA3176574A1 (https=)
DE (1) DE202021004005U1 (https=)
IL (1) IL296701A (https=)
MX (1) MX2022012600A (https=)
WO (1) WO2021204994A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3733712T (lt) 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
WO2022219057A1 (en) * 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
WO2012018704A1 (en) * 2010-08-02 2012-02-09 Sanofi-Aventis U.S. Llc Use of teriflunomide for treating multiple sclerosis
EP2748198A2 (en) * 2011-09-27 2014-07-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
LT3733712T (lt) * 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
MX2022003010A (es) * 2019-09-11 2022-06-02 Novartis Ag Tratamiento de la emr mediante cambio de terapia.
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
WO2022219057A1 (en) * 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients
US20240343821A1 (en) * 2021-08-16 2024-10-17 Novartis Ag Ofatumumab for treating pediatric ms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bar-Or, A. et al.，Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study，Neurology，2018年，Vol.90, No.20，p.e1805-e1814， doi:10.1212/WNL.0000000000005516

Also Published As

Publication number Publication date
JP2023521754A (ja) 2023-05-25
EP4682171A2 (en) 2026-01-21
DE202021004005U1 (de) 2022-05-06
BR112022019038A2 (pt) 2022-11-01
EP4682171A3 (en) 2026-05-06
CA3176574A1 (en) 2021-10-14
US20230151106A1 (en) 2023-05-18
WO2021204994A1 (en) 2021-10-14
EP4132564A1 (en) 2023-02-15
MX2022012600A (es) 2023-02-15
EP4707302A2 (en) 2026-03-11
KR20220166827A (ko) 2022-12-19
IL296701A (en) 2022-11-01
JP2026009900A (ja) 2026-01-21
CN115427068A (zh) 2022-12-02
AU2021253674A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
JP2026009900A (ja) 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ
EP3864053B1 (en) Treatment of rms by switching therapy
US20240228647A1 (en) Ofatumumab for treating multiple sclerosis in asian patients
Gensicke et al. Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis
JP2024531314A (ja) 小児ｍｓを治療するためのオファツムマブ
TW202300523A (zh) 用於治療MS同時維持血清IgG之奧法木單抗(OFATUMUMAB)
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
BR122024017958A2 (pt) Usos de ofatumumab para tratamento de esclerose múltipla (em) enquanto mantém a igg sérica
TW202222829A (zh) 治療皮膚型紅斑狼瘡及全身性紅斑狼瘡之方法
JP2022548004A (ja) オマリズマブを使用した治療方法
HK40051003A (en) Treatment of rms by switching therapy
HK40051003B (en) Treatment of rms by switching therapy
CN117015397A (zh) 用于治疗狼疮的方法和组合物
JP2026501785A (ja) 自己免疫疾患の治療のための抗ｃｄ３８抗体
WO2021111377A2 (en) Methods of treating lichen planus using interleukin-17 (il-17) antagonists
JP2024516019A (ja) 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240408

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250911

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251218

R150 Certificate of patent or registration of utility model

Ref document number: 7794757

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150